TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Mach7 Technologies ( (AU:M7T) ).
Mach7 Technologies has signed a 5-year subscription license agreement with UnityPoint Health for its new Flamingo Architecture product, marking the first commercial deployment of this modular offering. This agreement is expected to contribute significantly to Mach7’s annual recurring revenue, starting at approximately A$0.6 million and potentially growing to A$1 million over five years, as usage increases. This deal highlights Mach7’s strategic shift and potential for growth in the healthcare imaging industry.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies is a leading provider of medical imaging software, offering advanced data management and diagnostic viewing solutions to healthcare organizations globally. Their Enterprise Imaging Solution combines a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications, supporting a diverse network from large integrated delivery networks to private radiology practices.
Average Trading Volume: 273,141
Technical Sentiment Signal: Hold
Current Market Cap: A$110.4M
For a thorough assessment of M7T stock, go to TipRanks’ Stock Analysis page.